<DOC>
	<DOCNO>NCT02923193</DOCNO>
	<brief_summary>Shockwave Medical Inc. intend conduct prospective , multi-center , single blind , randomize ( 1:1 ) study Lithoplasty treatment use combination DCB versus standard balloon angioplasty use combination DCB treat moderate severely calcified femoropopliteal artery . Assuming roughly 15 % subject lost-to-follow-up , total 334 subject ( 167 per treatment arm ) enrol study .</brief_summary>
	<brief_title>Shockwave Medical Peripheral Lithoplasty System Study PAD ( Disrupt PAD III )</brief_title>
	<detailed_description>Shockwave Medical Inc. intend conduct prospective , multi-center , single blind , randomize ( 1:1 ) study Lithoplasty treatment use combination DCB versus standard balloon angioplasty use combination DCB treat moderate severely calcified femoropopliteal artery . The Shockwave Medical Peripheral Lithoplasty System indicate lithotripsy-enhanced , low-pressure balloon dilatation calcify , stenotic peripheral artery patient candidate percutaneous therapy . Up 334 subject 45 site Europe , United States New Zealand . Subjects follow discharge , 30 day , 6 , 12 24 month . DUS assessment complete 12 24 month . Procedural success define residual stenosis &lt; 30 % prior DCB stenting angiographic core lab .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Subject able willing comply assessment study . 2 . Subject subject 's legal representative inform nature study , agree participate sign approve consent form . 3 . Age subject &gt; 18 . 4 . Rutherford Clinical Category 2 , 3 , 4 target limb . 5 . Estimated life expectancy &gt; 1 year . 6 . Subject suitable candidate angiography endovascular intervention opinion investigator per hospital guideline . 7 . Subject intend undergo treatment Lithoplasty follow DCB DCB standard balloon predilatation . Angiographic Inclusion Criteria 8 . Target lesion locate native , de novo superficial femoral artery ( SFA ) popliteal artery ( popliteal 9 . Target lesion reference vessel diameter 4.0mm 7.0mm visual estimate . 10 . Target lesion ≥70 % stenosis investigator via visual estimate . 11 . Target lesion length 50180mm lesion 7099 % stenosed . Target lesion part 180mm treat zone . 12 . Chronic total occlusion lesion length ≤100mm . 13 . Subject least one patent tibial vessel target leg runoff foot , define stenosis &gt; 50 % . 14 . Calcification least moderate define presence fluoroscopic evidence calcification : 1 ) parallel side vessel 2 ) extend &gt; 50 % length lesion . Rutherford Clinical Category 0 , 1 , 5 6 . 2 . Subject active infection require antibiotic therapy . 3 . Planned target limb major amputation ( ankle ) . 4 . History prior endovascular surgical procedure index limb within past 30 day plan within 30 day index procedure . 5 . Subject know coagulopathy bleeding diatheses , thrombocytopenia platelet count less 100,000/microliter . 6 . Subject antiplatelet anticoagulant therapy contraindicate . 7 . Subject know allergy contrast agent medication use perform endovascular intervention adequately pretreated . 8 . Subject know allergy urethane , nylon , silicone . 9 . Myocardial infarction within 60 day prior enrollment . 10.History stroke within 60 day prior enrollment . 11.History thrombolytic therapy within two week enrollment . 12.Subject acute chronic renal disease ( e.g. , measure serum creatinine &gt; 2.5 mg/dL &gt; 220 umol/L ) , dialysis . 13.Subject pregnant nursing . 14.Subject participate another research study involve investigational agent ( pharmaceutical , biologic , medical device ) reach primary endpoint . 15.Subject medical , social psychological problem , opinion investigator , preclude receive treatment , procedure evaluation pre posttreatment . 16.The use specialty balloon , reentry atherectomy device . Angiographic Exclusion Criteria 17.Instent restenosis within target zone . 18.Lesions extend common femoral superficial femoral artery within 10 mm ostium anterior tibial artery . 19.Evidence aneurysm thrombus target vessel . 20.No calcium mild calcium target lesion . 21.Target lesion within native synthetic vessel graft . 22.Subject significant stenosis ( &gt; 50 % stenosis ) occlusion inflow tract target treatment zone ( e.g . iliac common femoral ) successfully treat . 23.Subject require treatment peripheral lesion ipsilateral limb distal target site time index procedure . 24.Unable pas guidewire across target lesion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>